BCRX

Biocryst Pharma's Orladeyo Approved In Mexico For Hereditary Angioedema Attacks

(RTTNews) - Monday, BioCryst Pharmaceuticals, Inc. (BCRX) announced the approval of its once-daily oral prophylactic treatment, Orladeyo also known as berotralstat, for preventing hereditary angioedema attacks in adults and pediatric patients aged 12 and above by the Federal Commission for Protection against Health Risks or COFEPRIS in Mexico.

The company stated that it holds an exclusive partnership with Pint Pharma GmbH to register and market Orladeyo in the pan-Latin America area.

According to the agreement, Pint is tasked with securing and managing all marketing authorizations and handling the commercialization of Orladeyo in Latin America.

The company revealed that Orladeyo had previously received approval from regulatory bodies in Chile, Argentina, and Brazil in this region.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.